XXXX polymorphism in the @entity7601 gene and @entity161 : relation to phenotype and drug response variability.

@entity1 @entity1088 @entity7601 @entity146 @entity161 @entity46076
Although genes play a major role in the etiology of @entity161 , no major genes involved in this disease have been identified. However, several genes with small effect have been reported, though inconsistently, to increase the risk for @entity161 . Recently, the @entity7601 2 allele ( @entity46076 polymorphism) was reported to be over-represented in @entity1 with @entity161 . Other reports have found an excess of allele 2(C) only in @entity161 @entity1 who are resistant to @entity1088 , not in those who respond to @entity1088 . In this study, the @entity7601 allele 2 frequencies were compared between 2 groups of @entity1 with @entity161 (39 responders and 63 nonresponders) based on long-term outcome and response to typical neuroleptics. A control group of 90 healthy volunteers screened for @entity146 was also included. Genotype 2/2 tended to be more frequent in @entity1 with @entity161 with poor long-term outcome and poor response to typical neuroleptics (Bonferroni corrected p = 0.09). This difference was significant in @entity1 (Bonferroni corrected p = 0.054) but not in @entity1 . In addition, the age at first contact with @entity146 care was significantly younger in the @entity1 with @entity161 with genotype 2/2 than in @entity1 with genotype 1/1. These result suggest that the @entity7601 gene may play a role in a subset of @entity161 characterized by poor long-term outcome and poor response to neuroleptics.
